title: Pharmacologic boosting of atazanavir in maintenance HIV-1 therapy: the COREYA propensity-score adjusted study.
abstract: BACKGROUND
  Among HIV-1 infected patients who achieved virologic suppression, the use of atazanavir without pharmacologic boosting is debated. We evaluated the efficacy and tolerance of maintenance therapy with unboosted atazanavir in clinical practice.
  
  
  RESULTS
  This multicenter retrospective cohort study evaluated the efficacy of switching HIV-1-infected patients controlled on triple therapy to unboosted (ATV(0), n = 98) versus ritonavir-boosted atazanavir (ATV/r, n = 254) +2 nucleos(t)ide reverse transcriptase inhibitors. The primary endpoint was time to virologic failure (VF, >200 copies/mL). ATV groups were compared controlling for potential confounding bias by inverse probability weighted Cox analysis and propensity-score matching. Overall and adjusted VF rates were similar for both strategies. Both strategies improved dyslipidemia and creatininemia, with less jaundice in the ATV(0) group.
  
  
  CONCLUSIONS
  In previously well-suppressed patients, within an observational cohort setting, ATV(0)-based triple-therapy appeared as effective as ATV/r- based triple-therapy to maintain virologic suppression, even if co-administered with TDF, but was better tolerated.
authors.affiliation: Service des Maladies Infectieuses et Tropicales, Centre Hospitalier Régional, Orléans, France.
authors.forename: Laurent
authors.initials: L
authors.lastname: Hocqueloux
authors.forename: Philippe
authors.initials: P
authors.lastname: Choisy
authors.forename: Gwenaël
authors.initials: G
authors.lastname: Le Moal
authors.forename: Françoise
authors.initials: F
authors.lastname: Borsa-Lebas
authors.forename: David
authors.initials: D
authors.lastname: Plainchamp
authors.forename: Eric
authors.initials: E
authors.lastname: Legac
authors.forename: Thierry
authors.initials: T
authors.lastname: Prazuck
authors.forename: Xavier
authors.initials: X
authors.lastname: de la Tribonnière
authors.forename: Yazdan
authors.initials: Y
authors.lastname: Yazdanpanah
authors.forename: Jean-Jacques
authors.initials: JJ
authors.lastname: Parienti
mesh_terms: D019380:Anti-HIV Agents / Q000494:pharmacology* / Q000627:therapeutic use; D000069446:Atazanavir Sulfate; D023381:Endpoint Determination; D015658:HIV Infections / Q000188:drug therapy / Q000821:virology; D015497:HIV-1 / Q000187:drug effects*; D006801:Humans; D053208:Kaplan-Meier Estimate; D009842:Oligopeptides / Q000494:pharmacology* / Q000627:therapeutic use; D011725:Pyridines / Q000494:pharmacology* / Q000627:therapeutic use; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D019380:Anti-HIV Agents; D009842:Oligopeptides; D011725:Pyridines; D000069446:Atazanavir Sulfate